Last reviewed · How we verify
NCT03408769: SexoMBC
Metastatic Breast Carcinoma and Women Sexual Quality of Life
trial testing Medical questionnaire in Metastatic Breast Carcinoma in 30 participants. Completed in 4 April 2018.
4 April 2018
Quick facts
| Lead sponsor | Institut de Cancérologie de Lorraine |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 12 March 2018 |
| Primary completion | 4 April 2018 |
| Estimated completion | 4 April 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- Medical questionnaire
Conditions studied
- Metastatic Breast Carcinoma — all drugs for Metastatic Breast Carcinoma →
Sponsor
Institut de Cancérologie de Lorraine — full company profile →
Who can join
Adults 50 to 70, female only, with Metastatic Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sexual health is one of the relevant parameters for assesing the quality of life. Improvement sexual and emotional function improves quality of life scores and depression or anxiety in curative phase. The purpose of the study is to assess the quality of sexual life of postmenopausal women with metastatic breast cancer in couples and to establish links with overall quality of life and the quality of the relationship.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03408769
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Medical questionnaire
Trials testing the same drug.
- NCT04906863 — Genetic Studies of Early-onset Dementia · recruiting
- NCT03003169 — Mastectomy in Ambulatory Breast Surgery · completed
Other recruiting trials for Metastatic Breast Carcinoma
Currently open trials in the same condition.
- NCT07137416 — Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for H · Phase 1 · recruiting
- NCT06860815 — Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Br · Phase 2 · recruiting
- NCT06502691 — [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Ca · Phase 1, PHASE2 · recruiting
- NCT07158021 — Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial · Phase 2 · recruiting
- NCT07227038 — Living Well With Advanced Breast Cancer · recruiting
Other Institut de Cancérologie de Lorraine trials
Trials by the same sponsor.
- NCT07326800 — Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) Among Patients Treated For Breast Cance · NA · recruiting
- NCT07089485 — Impact of Anesthesia Alarm Volume on Mental Workload in Surgical Trainees · NA · not yet recruiting
- NCT07165756 — "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot S · recruiting
- NCT06884332 — Spinal Palliation in Irradiation for Neoplastic Analgesia and Life Quality · NA · recruiting
- NCT06903104 — Acceptability and Feasibility of a Stress Prevention Program Based on Meditation and Acceptance and Commitment Therapy f · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03408769 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut de Cancérologie de Lorraine
- Last refreshed: 8 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03408769.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing